Tiziana Life Sci Plc (TILS) Article on Clinical Activity of OKT3 June 24, 2019 – Posted in: Tiziana Life Sciences (TILS)

Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform    Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a dose of 1 mg of OKT3 Tiziana’s…

Continue reading